<?xml version="1.0" encoding="UTF-8"?>
<p>The third and last anti-viral drug tested in a 70-patient clinical trial in Shenzhen, Guangdong province, is favilavir, which demonstrated efficacy in treating COVID-19, and with minor side effects. This drug was the first to get the approval to treat COVID-19 from the National Medical Products Administration of China [
 <xref rid="B26" ref-type="bibr">26</xref>].
</p>
